首页 › 期刊 › 医学 › Journal of Gastrointestinal Oncology
Journal of Gastrointestinal Oncology
出版商:AME Publishing Company · ISSN:2078-6891, 2219-679X · 国家/地区:HK · 类型:journal · OA 开放获取 · 官网:http://www.thejgo.org/index.php/jgo
研究主题:Gastric Cancer Management and Outcomes · Hepatocellular Carcinoma Treatment and Prognosis · Pancreatic and Hepatic Oncology Research · Cholangiocarcinoma and Gallbladder Cancer Studies · Esophageal Cancer Research and Treatment
数据覆盖:9 个公开学术数据源交叉核验(crossref、fqb、jcr、openalex、scimago、wikidata、xr、cwts、jufo)。
数据来源与实体核验
期刊官网 · OpenAlex 期刊实体 · Wikidata 期刊实体
核心指标
- 影响因子(JCR 2025):2.100
- JCR 分区:Q3(GASTROENTEROLOGY & HEPATOLOGY)
- 中科院分区(2025):医学 4区,大类排名 3474/5603;小类:GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学 4区,排名 100/143
- 新锐分区(2026):医学 4区
- SJR:0.659(Q2),2025 年,Hong Kong
- CWTS 2025:SNIP 0.592 · IPP 2.142 · 自引率 3.2%
- JUFO 出版渠道等级:芬兰 1 · 挪威 1
- h-index:57
- i10 指数:760
- 近两年篇均被引:1.94
- 载文量 2242 · 总被引 25479
- Crossref DOI 总量:2239,近期 689
逐年趋势
- 近年影响因子:2020 2.89 → 2021 2.59 → 2022 2.1 → 2023 2 → 2024 2
- 近年 SJR:2021 0.697(Q2) → 2022 0.606(Q3) → 2023 0.6(Q3) → 2024 0.687(Q2) → 2025 0.659(Q2)
同学科期刊推荐
- CA-A CANCER JOURNAL FOR CLINICIANS — IF 685.2 · JCR Q1 · 中科院1区(Top)
- The Lancet — IF 109.0 · JCR Q1 · 中科院1区(Top)
- MMWR Surveillance Summaries — IF 96.9 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Clinical Oncology — IF 94.6 · JCR Q1 · 中科院1区(Top)
- Nature Reviews Drug Discovery — IF 91.2 · JCR Q1 · 中科院1区(Top)
- New England Journal of Medicine — IF 84.5 · JCR Q1 · 中科院1区(Top)
- Signal Transduction and Targeted Therapy — IF 81.2 · JCR Q1 · 中科院1区(Top)
- Annals of Oncology — IF 80.4 · JCR Q1 · 中科院1区(Top)
常见问题
《Journal of Gastrointestinal Oncology》的影响因子是多少?
根据 JCR 2025 年数据,《Journal of Gastrointestinal Oncology》的最新影响因子(IF)为 2.100。
《Journal of Gastrointestinal Oncology》是几区期刊?
《Journal of Gastrointestinal Oncology》中科院分区(2025年版)为医学4区,JCR 分区为 Q3。
《Journal of Gastrointestinal Oncology》是开放获取(OA)期刊吗?
是,《Journal of Gastrointestinal Oncology》是开放获取(Open Access)期刊。
本刊近期代表论文
- Deciphering the tubulin code: roles and mechanisms of microtubule post-translational modifications in gastrointestinal tumors: a narrative review (2026)
- Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival (2025 · 被引 4)
- Tumor-informed circulating tumor DNA assay for surveillance post-liver transplantation in patients with hepatocellular and cholangiocarcinoma (2025 · 被引 4)
- Efficacy of stereotactic body radiotherapy in hepatocellular carcinoma with adrenal metastases: a retrospective analysis (2025 · 被引 3)
- Promotion of perineural invasion of cholangiocarcinoma by Schwann cells via nerve growth factor (2024 · 被引 10)
- Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study (2024 · 被引 8)